Pharmaceuticals, Biotechnology and Life Sciences
Trovagene has started erolling patients for its second phase study of onvansertib plus FOLFIRI and Avastin (bevacizumab) for second-line treatment of patients with metastatic colorectal cancer (mCRC) with a KRAS mutation.
BioNTech pulled one of the largest private EU biotech funding events expands global shareholder base with $325 from investors
– Selected by the FTSE4Good Developed Index for the 15th consecutive year – Named to the MSCI ESG Leaders Index…
Three late breakers, one oral presentation and 27 posters showcase AJOVY as a preventive treatment for migraine JERUSALEM & PARSIPPANY,…
ANN ARBOR, Mich.–(BUSINESS WIRE)–#AI–From making pain management safer and more effective to identifying inhibitors for a fibrosis target protein and…
Study achieved primary endpoint demonstrating pharmacokinetic bioequivalence between Captisol-enabled Iohexol and OMNIPAQUE™ SAN DIEGO–(BUSINESS WIRE)–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today…
Data shows 100% successful deployment and no fractures at 30-day follow-up in European Registry FLAGSTAFF, Ariz.–(BUSINESS WIRE)–W. L. Gore &…
Catalyst adopts unified platform approach to immediately offer impactful and competitive services for biopharmaceutical companies New full service offerings adopt…
DUBLIN–(BUSINESS WIRE)–The “Proton Pump Inhibitors (PPIs) Market by Product and Geography – Global Forecast and Analysis 2019-2023” report has been…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create…